EMA Authorised: Izba (travoprost) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Izba, a travoprost eye drop by Novartis Europharm Limited, for ocular hypertension and open-angle glaucoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma Open-angle
• Ocular Hypertension

Drugs mentioned

• Izba (travoprost)

Snippet

Status: Authorised. Therapeutic area: Ocular Hypertension;Glaucoma, Open-Angle. MAH: Novartis Europharm Limited. Decision date: 22/01/2025